

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/046716 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/26**,  
38/28, A61P 3/04, 3/10

DK-2800 Lyngby (DK). **SCHLEIN, Morten** [DK/DK];  
Under Elmene 16, 4.tv., DK-2300 København S (DK).

(21) International Application Number:  
PCT/DK2004/000788

(74) Common Representative: **NOVO NORDISK A/S**; Novo  
Allé, DK-2880 Bagsværd (DK).

(22) International Filing Date:  
12 November 2004 (12.11.2004)

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2003 01689 13 November 2003 (13.11.2003) DK

(71) Applicant (*for all designated States except US*): **NOVO  
NORDISK A/S** [DK/DK]; Novo Allé, DK-2880 Bagsværd  
(DK).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KNUDSEN,  
Liselotte Bjerre** [DK/DK]; Svallerup Søvej 16, DK-4400  
Kalundborg (DK). **HANSEN, Kristian Tage** [DK/DK];  
Strandstræde 12A, DK-3550 Slangerup (DK). **EN-  
GELUND, Dorthe Kot** [DK/DK]; Gassehaven 39,  
DK-2840 Holte (DK). **LUDVIGSEN, Svend** [DK/DK];  
Baunedalen 13, DK-3540 Lynge (DK). **HANSEN, Lars**  
[DK/DK]; Gammel Kongevej 152A, 1 tv, DK-1850 Fred-  
eriksberg C (DK). **BONDE, Claude** [FR/DK]; Borgevej 41  
B, DK-2800 Lyngby (DK). **JENSEN, Ejvind** [DK/DK];  
Nordvangsparken 16, DK-3460 Birkerød (DK). **BØVING,  
Tine Elisabeth Gottschalk** [DK/DK]; Boveskovvej 4,


Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: SOLUBLE PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION COMPRISING A  
GLP-1 PEPTIDE AND A INSULIN PEPTIDE OF SHORT TIME ACTION FOR TREATMENT OF DIABETES AND BULIMIA

Mean disappearance +/- SD



(57) Abstract: Pharmaceutical composition for  
parenteral administration comprising a meal related  
insulin peptide and an insulinotropic peptide.

WO 2005/046716 A1

SOLUBLE PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION COMPRISING A GLP-1 PEPTIDE AND A INSULIN PEPTIDE OF SHORT TIME ACTION FOR TREATMENT OF DIABETES AND BULIMIA

## FIELD OF THE INVENTION

5

The present invention relates to the field of pharmaceutical compositions. More specifically the invention pertains to pharmaceutical compositions comprising two different pharmaceutically active peptides.

## 10 BACKGROUND OF THE INVENTION

Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is partly or completely lost. About 5% of all people suffer from diabetes and the disorder approaches epidemic proportions. Since the introduction of insulin in the 1920's, continuous efforts have been made to improve the treatment of diabetes mellitus. Since people suffering from diabetes are subject to chronic treatment over several decades, there is a major need for safe, convenient and life quality improving insulin formulations.

In the treatment of diabetes mellitus, many varieties of insulin formulations have been suggested and used, such as regular insulin, isophane insulin (designated NPH), insulin zinc suspensions (such as Semilente<sup>®</sup>, Lente<sup>®</sup>, and Ultralente<sup>®</sup>), and biphasic isophane insulin. Some of the commercial available insulin formulations are characterized by a fast onset of action and other formulations have a relatively slow onset but show a more or less prolonged action. Fast-acting insulin formulations are usually solutions of insulin, while retarded acting insulin formulations can be suspensions containing insulin in crystalline and/or amorphous form precipitated by addition of zinc salts alone or by addition of protamine or by a combination of both.

Normally, insulin formulations are administered by subcutaneous injection. What is important for the patient is the action profile of the insulin formulation which is the action of insulin on the glucose metabolism as a function of the time from the injection. In this profile, inter alia, the time for the onset, the maximum value, and the total duration of action are important. A variety of insulin formulations with different action profiles are desired and requested by the patients.

Human insulin consists of two polypeptide chains, the so-called A and B chains which contain 21 and 30 amino acid residues, respectively. The A and B chains are interconnected by

two cystine disulphide bridges. Insulin from most other species has a similar construction, but may not contain the same amino acid residues at the same positions. Within the last decade a number of human insulin analogues have been developed. They are designed for particular profiles of action, i.e. fast acting or prolonged action.

5

Another peptide expected to become very important in the treatment of diabetes is glucagon-like peptide-1 (GLP-1). Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesized *i.a.* in the L-cells in the distal ileum, in the pancreas and in the brain. GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. GLP-1 stimulates insulin secretion in a glucose-dependant manner, stimulates insulin biosynthesis, promotes beta cell rescue, decreases glucagon secretion, gastric emptying and food intake. A simple system is used to describe fragments and analogues of this peptide. Thus, for example, Gly<sup>8</sup>-GLP-1(7-37) designates an analogue of GLP-1(7-37) formally derived from GLP-1(7-37) by substituting the naturally occurring amino acid residue in position 8 (Ala) by Gly. Similarly, Lys<sup>34</sup>(N<sup>ε</sup>-tetradecanoyl)-GLP-1(7-37) designates GLP-1(7-37) wherein the  $\epsilon$ -amino group of the Lys residue in position 34 has been tetradecanoylated. PCT publications WO 98/08871 and WO 99/43706 disclose stable derivatives of GLP-1 analogues, which have a lipophilic substituent. These stable derivatives of GLP-1 analogues have a protracted profile of action compared to the corresponding GLP-1 analogues.

As the type 2 diabetes population is rapidly increasing in the world, there is a much larger need for simpler administration of more effective drugs. The combined effects of GLP-1 are expected to give very effective and safe lowering of blood glucose. However, some patients may benefit from an extra small dose of insulin with the main meals. A combination formulation comprising an insulin peptide and a GLP-1 peptide, may with a fixed ratio of the two pharmaceuticals, be a very efficacious treatment as well as one requiring less injections when administered to the same patient. Because only a low dose of insulin is given with the meal and the GLP-1 counterpart of the formulation controls glucose for the rest of the day and night, and since GLP-1 does not lead to hypoglycaemia it may also be a very safe treatment.

Thus, there is a big need for stable pharmaceutical compositions comprising meal-related insulin and a GLP-1 peptide in one combined formulation.

30

**BREIF DESCRIPTION OF THE DRAWINGS**

Figure 1. Average disappearance curves showing the disappearance of radiolabeled insulin aspart.

5 Figure 2. Plasma levels of liraglutide after subcutaneous injections of the mixtures (logarithmic scale).

Figure 3. Plasma levels of liraglutide after subcutaneous injections of the mixtures (linear scale).

10 Figure 4. Turbidimetric measurements of two pharmaceutical compositions containing aspart and liraglutide. Pharmaceutical composition without poloxamer 188 (x) and with poloxamer 188 (◇) (500 ppm).

Figure 5. Turbidimetric measurements of two pharmaceutical compositions containing aspart and liraglutide. Pharmaceutical composition without poloxamer 188 (x) and with poloxamer 188 (◇) (50 ppm).

15 Figure 6. All samples contain: 0.6 mM insulin aspart, 0.3 mM Zn(Ac)<sub>2</sub>, 1.2 mM Liraglutide, 14 mg/ml propylene glycol, 40 mM phenol, 10 mM NaCl, pH 7.7. Poloxamer 188 is added to two of the samples.

20 Figure 7. Both samples contain 0.6 mM insulin aspart, 0.3 mM Zn(Ac)<sub>2</sub>, 1.2 mM Liraglutide, 40 mM phenol, 14 mg/ml propylene glycol, 10 mM NaCl, pH 7.7. Polysorbate 20 is added to one sample.

Figure 8. All samples contain 0.6 mM insulin aspart, 0.3 mM Zn(Ac)<sub>2</sub>, 1.2 mM Liraglutide, 8 mM sodium phosphate pH 7.7, 40 mM phenol, 14 mg/ml propylene glycol. Poloxamer 188 is added to two samples.

25 Figure 9. 0.6 mM insulin aspart, 0.3 mM Zn(Ac)<sub>2</sub>, 1.2 mM Liraglutide, 8 mM sodium phosphate, 40 mM phenol, 14 mg/ml propylene glycol, pH 7.7. Polysorbate 20 is added to two of the samples.

**SUMMARY OF THE INVENTION**

30 One object of the present invention is to provide a soluble pharmaceutical composition for parenteral administration, which comprises an insulinotropic peptide, a meal related insulin peptide, a pharmaceutically acceptable preservative and optionally an isotonicity agent. In one embodiment of the invention, pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from about pH 7.0 to about pH 9.0.

In another embodiment of the invention, pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from about pH 7.0 to about pH 8.0.

Another object of the invention is to provide a method for the treatment of hyperglycemia comprising parenteral administration of an effective amount of a soluble pharmaceutical composition comprising an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative and optionally an isotonicity agent.

## 10 DEFINITIONS

The following is a detailed definition of the terms used in the specification.

The term "effective amount" as used herein means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment.

15 The term "medicament" as used herein means a pharmaceutical composition suitable for administration of the pharmaceutically active compounds to a patient.

The term "pharmaceutical composition" as used herein means a product comprising an active compound or a salt thereof together with pharmaceutical excipients such as buffer, preservative and tonicity modifier, said pharmaceutical composition being useful for treating, preventing or reducing the severity of a disease or disorder by administration of said pharmaceutical composition to a person. Thus a pharmaceutical composition is also known in the art as a pharmaceutical formulation.

The term "soluble pharmaceutical composition" as used herein means an insulinotropic peptide which is substantially soluble, and a meal-related insulin peptide which is substantially soluble in the combined composition. Thus, a predissolved soluble pharmaceutical composition will be substantially soluble, and a soluble pharmaceutical composition which is to be reconstituted will be substantially soluble once it has been dissolved in the prescribed reconstitution liquid. It is to be understood that pH of a pharmaceutical composition which is to be reconstituted is the pH value which is measured on the reconstituted composition produced by reconstitution in the prescribed reconstitution liquid at room temperature.

30 The term "pharmaceutically acceptable" as used herein means suited for normal pharmaceutical applications, i.e. giving rise to no adverse events in patients etc.

The term "buffer" as used herein refers to a chemical compound in a pharmaceutical composition that reduces the tendency of pH of the composition to change over time as

would otherwise occur due to chemical reactions. Buffers include chemicals such as sodium phosphate, TRIS, glycine and sodium citrate.

The term "preservative" as used herein refers to a chemical compound which is added to a pharmaceutical composition to prevent or delay microbial activity (growth and me-  
5 tabolism). Examples of pharmaceutically acceptable preservatives are phenol, m-cresol and a mixture of phenol and m-cresol.

The term "isotonicity agent" as used refers to a chemical compound in a pharmaceu-  
tical composition that serves to modify the osmotic pressure of the pharmaceutical composi-  
tion so that the osmotic pressure becomes closer to that of human plasma. Isotonicity agents  
10 include NaCl, glycerol, mannitol etc.

The term "stabilizer" as used herein refers to chemicals added to peptide containing  
pharmaceutical compositions in order to stabilize the peptide, i.e. to increase the shelf life  
and/or in-ude time of such compositions. Examples of stabilizers used in pharmaceutical  
formulations are L-glycine, L-histidine, arginine, polyethylene glycol, and carboxymethylcellu-  
15 lose.

The term "treatment of a disease" as used herein means the management and care  
of a patient having developed the disease, condition or disorder. The purpose of treatment is  
to combat the disease, condition or disorder. Treatment includes the administration of the  
active compounds to eliminate or control the disease, condition or disorder as well as to alle-  
20 viate the symptoms or complications associated with the disease, condition or disorder.

The term "prevention of a disease" as used herein is defined as the management  
and care of an individual at risk of developing the disease prior to the clinical onset of the  
disease. The purpose of prevention is to combat the development of the disease, condition  
or disorder, and includes the administration of the active compounds to prevent or delay the  
25 onset of the symptoms or complications and to prevent or delay the development of related  
diseases, conditions or disorders.

The term "insulin peptide" as used herein means a peptide which is either human in-  
sulin or a chemically modified human insulin, such as an analog or a derivative thereof.

The term "human insulin" as used herein means the human hormone whose struc-  
30 ture and properties are well known. Human insulin has two polypeptide chains that are con-  
nected by disulphide bridges between cysteine residues, namely the A-chain and the B-  
chain. The A-chain is a 21 amino acid peptide and the B-chain is a 30 amino acid peptide,  
the two chains being connected by three disulphide bridges : one between the cysteines in  
position 6 and 11 of the A-chain, the second between the cysteine in position 7 of the A-

chain and the cysteine in position 7 of the B-chain, and the third between the cysteine in position 20 of the A-chain and the cysteine in position 19 of the B-chain.

The term "analogue" as used herein referring to a peptide means a modified peptide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been deleted from the peptide and or wherein one or more amino acid residues have been added to the peptide. Such addition or deletion of amino acid residues can take place at the N-terminal of the peptide and/or at the C-terminal of the peptide.

The term "derivative" as used herein in relation to a parent peptide means a chemically modified parent protein or an analogue thereof, wherein at least one substituent is not present in the parent protein or an analogue thereof, i.e. a parent protein which has been covalently modified. Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters, PEGylations and the like. Examples of derivatives of human insulin are threonine methyl ester<sup>B30</sup> human insulin and N<sup>εB29</sup>-tetradecanoyl des(B30) human insulin.

The term "meal-related insulin peptide" as used herein means an insulin peptide which has a time-action of less than 8 hours in standard models of diabetes. Preferably, the meal-related human insulin has a time-action of less than about 5 hours. Preferably, the meal-related insulin has a time-action in the range from 0 hours to about 4 hours. Preferably, the meal-related insulin has a time-action similar to that observed for commercial pharmaceutical compositions of Actrapid<sup>®</sup>, Novolog<sup>®</sup>, and Humalog<sup>®</sup>. The term about in relation to the time-action of insulins means + or - 30 minutes.

The term "GLP-1 compound" as used herein means GLP-1(7-37) (SEQ ID NO. 1), insulinotropic analogue thereof and insulinotropic derivatives thereof. Non-limiting examples of GLP-1 analogues are GLP-1(7-36) amide, Arg<sup>34</sup>-GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>-GLP-1(7-36)-amide and Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-37). Non-limiting examples of GLP-1 derivatives are desamino-His<sup>7</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37), desamino-His<sup>7</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl)-GLP-1(7-37), Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>ε</sup>-(ω-carboxypentadecanoyl))-GLP-1(7-38), Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-36) and Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37).

The term "stable GLP-1 compound" as used herein means a chemically modified GLP-1(7-37), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by the following method. The method for determination of plasma elimination half-life of a peptide in man is : The compound is dissolved in an isotonic buffer, pH 7.4, PBS or any other suitable buffer. The dose is injected

peripherally, preferably in the abdominal or upper thigh. Blood samples for determination of active compound are taken at frequent intervals, and for a sufficient duration to cover the terminal elimination part (e.g. Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 (day 2), 36 (day 2), 48 (day 3), 60 (day 3), 72 (day 4) and 84 (day 4) hours post dose). Determination of the concentration of active compound is performed as described in Wilken et al., *Diabetologia* 43(51):A143, 2000. Derived pharmacokinetic parameters are calculated from the concentration-time data for each individual subject by use of non-compartmental methods, using the commercially available software WinNonlin Version 2.1 (Pharsight, Cary, NC, USA). The terminal elimination rate constant is estimated by log-linear regression on the terminal log-linear part of the concentration-time curve, and used for calculating the elimination half-life.

The term "dipeptidyl aminopeptidase IV protected GLP-1 compound" as used herein means a GLP-1 compound which is more resistant to the plasma peptidase dipeptidyl aminopeptidase IV (DPP-IV) than the native GLP-1 agonist, GLP-1(7-37). Resistance of a GLP-1 compound towards degradation by dipeptidyl aminopeptidase IV is determined by the following degradation assay :

Aliquots of the GLP-1 compound (5 nmol) are incubated at 37 °C with 1 µL of purified dipeptidyl aminopeptidase IV corresponding to an enzymatic activity of 5 mU for 10-180 minutes in 100 µL of 0.1 M triethylamine-HCl buffer, pH 7.4. Enzymatic reactions are terminated by the addition of 5 µL of 10% trifluoroacetic acid, and the peptide degradation products are separated and quantified using HPLC analysis. One method for performing this analysis is : The mixtures are applied onto a Vydac C18 widepore (30 nm pores, 5 µm particles) 250 x 4.6 mm column and eluted at a flow rate of 1 ml/min with linear stepwise gradients of acetonitrile in 0.1% trifluoroacetic acid (0% acetonitrile for 3 min, 0-24% acetonitrile for 17 min, 24-48% acetonitrile for 1 min) according to Siegel et al., *Regul. Pept.* 1999;79:93-102 and Mentlein et al. *Eur. J. Biochem.* 1993;214:829-35. Peptides and their degradation products may be monitored by their absorbance at 220 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of their peak areas related to those of standards. The rate of hydrolysis of a GLP-1 compound by dipeptidyl aminopeptidase IV is estimated at incubation times which result in less than 10% of the GLP-1 compound being hydrolysed.

The term "insulinotropic" as used herein referring to a peptide or a compound means the ability to stimulate secretion of insulin in response to an increased plasma glucose level. Insulinotropic peptides and compounds are agonists of the GLP-1 receptor. The insulinotropic property of a compound may be determined by in vitro or in vivo assays known in the art. The following in vitro assay may be used to determine the insulinotropic nature of a com-

pound such as a peptide. Preferably insulinotropic compounds exhibit an  $EC_{50}$  value in below assay of less than 5 nM, even more preferably  $EC_{50}$  values less than 500 pM.

Baby hamster kidney (BHK) cells expressing the cloned human GLP-1 receptor (BHK 467-12A) are grown in DMEM media with the addition of 100 IU/mL penicillin, 100  
5  $\mu$ L/mL streptomycin, 10% foetal calf serum and 1 mg/mL Geneticin G-418 (Life Technologies). Plasma membranes are prepared by homogenization in buffer (10 mM Tris-HCl, 30 mM NaCl and 1 mM dithiothreitol, pH 7.4, containing, in addition, 5 mg/mL leupeptin (Sigma), 5 mg/L pepstatin (Sigma), 100 mg/L bacitracin (Sigma), and 16 mg/L aprotinin (Calbiochem-Novabiochem, La Jolla, CA)). The homogenate was centrifuged on top of a layer of 41%  
10 W7v sucrose. The white band between the two layers was diluted in buffer and centrifuged. Plasma membranes were stored at -80 °C until used.

The functional receptor assay is carried out by measuring cAMP as a response to stimulation by the insulinotropic peptide or insulinotropic compound. Incubations are carried out in 96-well microtiter plates in a total volume of 140  $\mu$ L and with the following final concentrations:  
15 50 mM Tris-HCl, 1 mM EGTA, 1.5 mM  $MgSO_4$ , 1.7 mM ATP, 20 mM GTP, 2 mM 3-isobutyl-1-methylxanthine (IBMX), 0.01% w/v Tween-20, pH 7.4. Compounds are dissolved and diluted in buffer. GTP is freshly prepared for each experiment: 2.5  $\mu$ g of membrane is added to each well and the mixture is incubated for 90 min at room temperature in the dark with shaking. The reaction is stopped by the addition of 25  $\mu$ L 0.5 M HCl. Formed cAMP is measured  
20 by a scintillation proximity assay (RPA 542, Amersham, UK). A dose-response curves is plotted for the compound and the  $EC_{50}$  value is calculated using GraphPad Prism software.

The term "prodrug of an insulinotropic compound" as used herein means a chemically modified compound which following administration to the patient is converted to an insulinotropic compound. Such prodrugs are typically amino acid extended versions or esters of  
25 an insulinotropic compound.

The term "exendin-4 compound" as used herein is defined as exendin-4(1-39) (SEQ ID NO. 2), insulinotropic fragments thereof, insulinotropic analogs thereof and insulinotropic derivatives thereof. Insulinotropic fragments of exendin-4 are insulinotropic peptides for which the entire sequence can be found in the sequence of exendin-4 (SEQ ID NO. 2) and  
30 where at least one terminal amino acid has been deleted. Examples of insulinotropic fragments of exendin-4(1-39) are exendin-4(1-38) and exendin-4(1-31). The insulinotropic property of a compound may be determined by in vivo or in vitro assays well known in the art. For instance, the compound may be administered to an animal and monitoring the insulin concentration over time. Insulinotropic analogs of exendin-4(1-39) refer to the respective molecules wherein one or more of the amino acids residues have been exchanged with other  
35

amino acid residues and/or from which one or more amino acid residues have been deleted and/or from which one or more amino acid residues have been added with the proviso that said analogue either is insulinotropic or is a prodrug of an insulinotropic compound. An example of an insulinotropic analog of exendin-4(1-39) is Ser<sup>2</sup>Asp<sup>3</sup>-exendin-4(1-39) wherein the amino acid residues in position 2 and 3 have been replaced with serine and aspartic acid, respectively (this particular analog also being known in the art as exendin-3). Insulinotropic derivatives of exendin-4(1-39) and analogs thereof are what the person skilled in the art considers to be derivatives of these peptides, i.e. having at least one substituent which is not present in the parent peptide molecule with the proviso that said derivative either is insulinotropic or is a prodrug of an insulinotropic compound. Examples of substituents are amides, carbohydrates, alkyl groups, esters and lipophilic substituents. An example of an insulinotropic derivatives of exendin-4(1-39) and analogs thereof is Tyr<sup>31</sup>-exendin-4(1-31)-amide.

The term "stable exendin-4 compound" as used herein means a chemically modified exendin-4(1-39), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by the method described under the definition of "stable GLP-1 compound".

The term "dipeptidyl aminopeptidase IV protected exendin-4 compound" as used herein means an exendin-4 compound which is more resistant towards the plasma peptidase dipeptidyl aminopeptidase IV (DPP-IV) than exendin-4 (SEQ ID NO. 2), as determined by the assay described under the definition of dipeptidyl aminopeptidase IV protected GLP-1 compound.

The term "isoelectric point" as used herein means the pH value where the overall net charge of a macromolecule such as a peptide is zero. In peptides there may be several charged groups, and at the isoelectric point the sum of all these charges is zero. At a pH above the isoelectric point the overall net charge of the peptide will be negative, whereas at pH values below the isoelectric point the overall net charge of the peptide will be positive.

The term "reconstituted" as used herein referring to a pharmaceutical composition means an aqueous composition which has been formed by the addition of water to a solid material comprising the active pharmaceutical ingredient. Pharmaceutical compositions for reconstitution are applied where a liquid composition with acceptable shelf-life cannot be produced. An example of a reconstituted pharmaceutical composition is the solution which results when adding water to a freeze dried composition. The solution is often for parenteral administration and thus water for injection is typically used for reconstituting the solid material.

The term "about" as used herein in relation to the concentration of a peptide in a pharmaceutical composition means plus or minus 10%. Hence, the concentration "about 5 mg/mL insulin" means a concentration of 4.5 mg/mL insulin to 5.5 mg/mL insulin.

5

## DESCRIPTION OF THE INVENTION

In one aspect the invention relates to a pharmaceutical composition for parenteral administration, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative and optionally an isotonicity agent.

In embodiment of the invention the pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from pH 7.0 to pH 9.0.

In embodiment of the invention the pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from pH 7.0 to pH 8.0.

In another embodiment of the invention the composition is a solution. In another embodiment of the invention the pharmaceutical composition is a solid. In another embodiment of the invention the pharmaceutical composition is to be reconstituted with an aqueous solution such as a buffer or water for injection.

In another embodiment of the invention the pharmaceutical composition is suitable for administration by injection or infusion. In another embodiment of the invention the pharmaceutical composition is suitable for subcutaneous administration. In another embodiment of the invention the pharmaceutical composition is suitable for intramuscular administration. In another embodiment of the invention the pharmaceutical composition is suitable for intravenous administration.

In a further embodiment the present invention relates to a pharmaceutical composition wherein the meal-related insulin peptide has a time action of less than 4 hours.

In another aspect the present invention relates to a pharmaceutical composition wherein said insulin peptide is human insulin, an analogue of human insulin, a derivative of human insulin or a derivative of a human insulin analogue.

In one embodiment of the invention said insulin peptide is human insulin.

In a further aspect the present invention relates to a pharmaceutical composition wherein said insulin peptide is a human insulin analogue. In one embodiment of the invention said human insulin analogue is Asp<sup>B28</sup>-human insulin. In another embodiment of the invention said human insulin analogue is Lys<sup>B28</sup>,Pro<sup>B29</sup>-human insulin. In another embodiment of the invention said human insulin analogue is Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin. In another embodiment of the invention said human insulin analogue is des(B30) human insulin. In another embodiment of the invention said insulin peptide is a derivative of a human insulin analogue.

In another embodiment of the invention the concentration of said meal-related insulin peptide in said pharmaceutical composition is in the range from about 1.6 mg/mL to about 5.6 mg/mL, or from about 2.6 mg/mL to about 4.6 mg/mL, or from about 3.2 mg/mL to about 4.0 mg/mL.

In another embodiment of the invention the concentration of said meal-related insulin peptide in said pharmaceutical composition is in the range from about 1 mg/mL to about 10 mg/mL, or from about 2.5 mg/mL to about 8.75 mg/mL, or from about 3.5 mg/mL to about 8.75 mg/mL, or from about 5 mg/mL to about 8.75 mg/mL.

In another embodiment of the invention the pharmaceutical composition comprises two different insulin peptides.

In another aspect the present invention relates to a pharmaceutical composition wherein said insulinotropic peptide is GLP-1(7-37) (SEQ ID NO. 1), a GLP-1(7-37) analogue, a derivative of GLP-1(7-37), or a derivative of a GLP-1(7-37) analogue. In another embodiment of the invention said GLP-1(7-37) analogue is selected from the group consisting of Arg<sup>34</sup>-GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-36)-amide, Gly<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Lys<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Lys<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Arg<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Arg<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>His<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>His<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>19</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Val<sup>25</sup>-GLP-1(7-37), Val<sup>8</sup>Tyr<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Leu<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Tyr<sup>18</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>His<sup>37</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Val<sup>25</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Val<sup>25</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Val<sup>25</sup>-GLP-1(7-37), analogues thereof and derivatives of any of these.

In another embodiment of the invention said insulinotropic peptide has a Glu residue in position 22. In another embodiment of the invention said insulinotropic peptide has a L-histidine residue in position 8. In another embodiment of the invention said insulinotropic peptide has

a Val residue in position 8. In another embodiment of the invention said derivative of a GLP-1(7-37) analogue is GLP-1(7-36)-amide.

In another aspect the present invention relates to a pharmaceutical composition wherein said  
5 insulinotropic peptide is a derivative of GLP-1(7-37) or a derivative of a GLP-1(7-37) ana-  
logue having a lysine residue, such as one lysine, wherein a lipophilic substituent optionally  
via a spacer is attached to the epsilon amino group of said lysine. In one embodiment of the  
invention said lipophilic substituent has from 8 to 40 carbon atoms, preferably from 8 to 24,  
eg 12-18. In another embodiment of the invention said spacer is present and is selected from  
10 an amino acid, eg. beta-Ala, L-Glu, aminobutyryl. In another embodiment of the invention  
said insulinotropic peptide is a dipeptidyl aminopeptidase IV protected GLP-1 compound. In  
another embodiment of the invention said insulinotropic peptide is a plasma stable GLP-1  
compound. In another embodiment of the invention said derivative of a GLP-1(7-37) ana-  
logue is Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37). In another embodiment of  
15 the invention said insulinotropic peptide has from 27 to 43 amino acid residues, preferable  
from 28 to 38 amino acid residues, even more preferable from 30 to 34 amino acid residues.  
In another embodiment of the invention the concentration of said insulinotropic peptide in  
said pharmaceutical composition is from about 1 mg/mL to about 25 mg/mL, from about 2  
mg/mL to about 15 mg/mL, from about 5 mg/mL to about 12 mg/mL, or from about 8 mg/mL  
20 to about 11 mg/mL. In another embodiment of the invention the concentration of said insuli-  
notropic peptide in said pharmaceutical composition is from about 5 mg/mL to about 7.5  
mg/mL.

In another aspect the present invention relates to a pharmaceutical composition wherein said  
25 insulinotropic peptide is exendin-4 (SEQ ID NO. 2), an exendin-4 analogue, a derivative of  
exendin-4, or a derivative of an exendin-4 analogue. In one embodiment of the invention said  
insulinotropic peptide is exendin-4 (SEQ ID NO. 2). In another embodiment of the invention  
said exendin-4 analogue is exendin-3 or ZP-10 (HGEGTFTSDLSKQMEEEEAVRL-  
FIEWLKNGGPSSGAPPSKKKKKK-NH<sub>2</sub>, SEQ ID NO. 3).

30 In another embodiment of the invention said derivative of an exendin-4 analogue is an acy-  
lated exendin-4 analogue or a pegylated exendin-4 analogue. In another embodiment of the  
invention said insulinotropic peptide is a derivative of exendin-4 or a derivative of an exendin-  
4 analogue having a lysine residue, such as one lysine, wherein a lipophilic substituent op-  
tionally via a spacer is attached to the epsilon amino group of said lysine. In another em-  
35 bodiment of the invention said lipophilic substituent has from 8 to 40 carbon atoms, prefera-

bly from 8 to 24, eg 12-18. In another embodiment of the invention said spacer is present and is selected from an amino acid, eg. beta-Ala, L-Glu, aminobutyroyl. In another embodiment of the invention said insulinotropic peptide is a dipeptidyl aminopeptidase IV protected exendin-4 compound. In another embodiment of the invention said insulinotropic peptide is a plasma stable exendin-4 compound. In another embodiment of the invention said insulinotropic peptide has from 30 to 48 amino acid residues, from 33 to 45 amino acid residues, preferable from 35 to 43 amino acid residues, even more preferable from 37 to 41 amino acid residues. In another embodiment of the invention the concentration of said insulinotropic peptide in said pharmaceutical composition is from about 5  $\mu\text{g/mL}$  to about 10 mg/mL, from about 5  $\mu\text{g/mL}$  to about 5 mg/mL, from about 0.1 mg/mL to about 3 mg/mL, or from about 0.2 mg/mL to about 1 mg/mL.

In another aspect the present invention relates to a pharmaceutical composition wherein the isoelectric point of said insulinotropic peptide is from 3.0 to 7.0, from 4.0 to 6.0, preferable from 4.2 to 5.5, even more preferable from 4.3 to 5.2.

In one aspect the present invention relates to a pharmaceutical composition which further comprises zinc. In one embodiment of the invention the molar ratio of zinc to insulin peptide is from 1/6 to  $\frac{1}{2}$  mole/mole, preferable from 3/12 to 5/12 mole/mole.

In another aspect the present invention relates to a pharmaceutical composition, wherein said meal-related insulin peptide is human insulin and said insulinotropic peptide is Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-( $\gamma$ -Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37). In one embodiment of the invention the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-( $\gamma$ -Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 1 mg/mL to about 25 mg/mL and the concentration of human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL. In another embodiment of the invention the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-( $\gamma$ -Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 5 mg/mL to about 15 mg/mL and the concentration of human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL.

In another aspect the present invention relates to a pharmaceutical composition, wherein said insulin peptide is Asp<sup>B28</sup>-human insulin and said insulinotropic peptide is Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-( $\gamma$ -Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37). In one embodiment of the invention the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-( $\gamma$ -Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 1 mg/mL to about 25 mg/mL and the concentration of Asp<sup>B28</sup>-human insulin is in the range

from about 3.2 mg/mL to about 4.0 mg/mL. In another embodiment of the invention the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from from about 5 mg/mL to about 15 mg/mL and the concentration of Asp<sup>B28</sup>-human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL. In another embodiment of the invention the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 1 mg/mL to about 25 mg/mL and the concentration of Asp<sup>B28</sup>-human insulin is in the range from about 3.4 mg/mL to about 3.8 mg/mL. In another embodiment of the invention the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 5 mg/mL to about 15 mg/mL and the concentration of Asp<sup>B28</sup>-human insulin is in the range from about 3.4 mg/mL to about 3.8 mg/mL.

In another aspect the present invention relates to a pharmaceutical composition, wherein said insulin peptide is Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin and said insulinotropic peptide is ZP-10 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH<sub>2</sub>, SEQ ID NO. 3). In one embodiment of the invention the concentration of Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL. In another embodiment of the invention the concentration of ZP-10 is in the range from about 0.1mg/mL to about 3mg/mL.

In another embodiment of the present invention the preservative is phenol, m-cresol or a mixture thereof.

In another aspect of the present invention the pharmaceutical composition comprises a buffer. In one embodiment of the invention said buffer is phosphate, TRIS, HEPES, glycine, N-glycylglycine, citrate or mixtures thereof.

In another aspect of the present invention the pharmaceutical composition comprises an isotonicity agent. In one embodiment the isotonicity agent is not a salt. In another embodiment the isotonicity agent is selected from mannitol, sorbitol, glycerol, propylene glycol or a mixture thereof.

In another aspect the present invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, a stabiliser and optionally an isotonicity agent. In one embodiment of the invention said stabiliser is selected from the group consisting of L-histidine, imidazole and L-arginine. In another embodiment of the invention said stabiliser is a polyethylene glycol.

In another aspect the present invention relates to a soluble pharmaceutical composition which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, a surfactant and optionally an isotonicity agent.

In one embodiment the surfactant is a poloxamer.

5 In another embodiment the surfactant is a poloxamer 188.

In another embodiment the surfactant is selected from the group consisting of poloxamer 407, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 237, poloxamer 331 and poloxamer 338.

In another embodiment the surfactant is a polysorbate 20 (Tween-20).

10 In another embodiment the concentration of said surfactant is from about 5 mg/L to about 3000 mg/L.

In another embodiment the concentration of said surfactant is from about 10 mg/L to about 500 mg/L.

15 In another embodiment the concentration of said surfactant is from about 20 mg/L to about 300 mg/L.

In another embodiment the concentration of said surfactant is from about 50 mg/L to about 200 mg/L.

In another embodiment the pharmaceutical composition comprises two different surfactants.

20 In another embodiment the pharmaceutical composition comprises poloxamer 188 and polysorbate 20 (Tween-20).

In another embodiment of the invention the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, such as poloxamer 188 and poloxamer 407, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives such as alkylated and alkoxyated derivatives  
25 (tweens, e.g. Tween-20, or Tween-80), monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, glycerol, cholic acid or derivatives thereof, lecithins, alcohols and phospholipids, glycerophospholipids (lecithins, kephalins, phosphatidyl serine), glyceroglycolipids (galactopyransoide), sphingophospholipids (sphingomyelin), and sphingoglycolipids (ceramides, gangliosides), DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), dipalmitoyl phosphatidic acid, sodium caprylate, bile acids and salts thereof and glycine or taurine conjugates, ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate, N-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, anionic (alkyl-aryl-sulphonates) monovalent surfactants, palmitoyl lysophosphatidyl-L-serine,  
35

lysophospholipids (e.g. 1-acyl-sn-glycero-3-phosphate esters of ethanolamine, choline, serine or threonine), alkyl, alkoxyl (alkyl ester), alkoxy (alkyl ether)- derivatives of lysophosphatidyl and phosphatidylcholines, e.g. lauroyl and myristoyl derivatives of lysophosphatidylcholine, dipalmitoylphosphatidylcholine, and modifications of the polar head group, that is

5 cholines, ethanolamines, phosphatidic acid, serines, threonines, glycerol, inositol, and the positively charged DODAC, DOTMA, DCP, BISHOP, lysophosphatidylserine and lysophosphatidylthreonine, zwitterionic surfactants (e.g. N-alkyl-N,N-dimethylammonio-1-propanesulfonates, 3-cholamido-1-propyldimethylammonio-1-propanesulfonate, dodecylphosphocholine, myristoyl lysophosphatidylcholine, hen egg lysolecithin), cationic surfactants

10 (quarternary ammonium bases) (e.g. cetyl-trimethylammonium bromide, cetylpyridinium chloride), non-ionic surfactants, polyethyleneoxide/polypropyleneoxide block copolymers (Pluronic/Tetronics, Triton X-100, Dodecyl  $\beta$ -D-glucopyranoside) or polymeric surfactants (Tween-40, Tween-80, Brij-35), fusidic acid derivatives- (e.g. sodium tauro-dihydrofusidate etc.), long-chain fatty acids and salts thereof C6-C12 (eg. oleic acid and caprylic acid), acylcarnitines and derivatives, N <sup>$\alpha$</sup> -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N <sup>$\alpha$</sup> -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N <sup>$\alpha$</sup> -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative

20 embodiment of the invention. In a further embodiment of the invention the surfactant is a polysorbate, such as polysorbate-20. In a further embodiment of the invention the pharmaceutical composition comprises a surfactant in a concentration from about 1 ppm to about 500 ppm, preferably from about 10 ppm to about 120 ppm.

25

In another aspect the present invention relates to a method for treatment of hyperglycemia comprising parenteral administration of an effective amount of a pharmaceutical composition, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, and optionally an isotonicity agent.

30

In another aspect the present invention relates to a method for treatment of binge eating or bulimia comprising parenteral administration of an effective amount of a pharmaceutical composition, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, and optionally an isotonicity agent.

35

In another aspect the present invention relates to a method for treatment or prevention of type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X,

dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory bowel syndrome, dyspepsia and gastric ulcers comprising parenteral administration of an effective amount of a pharmaceutical composition, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, and optionally an isotonicity agent.

In another aspect the present invention relates to a method for delaying or preventing disease progression in type 2 diabetes comprising parenteral administration of an effective amount of a pharmaceutical composition, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, and optionally an isotonicity agent.

In another aspect the present invention relates to a method for decreasing food intake, decreasing  $\beta$ -cell apoptosis, increasing  $\beta$ -cell function and  $\beta$ -cell mass, and/or for restoring glucose sensitivity to  $\beta$ -cells comprising parenteral administration of an effective amount of a pharmaceutical composition, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, and optionally an isotonicity agent.

When the pharmaceutical compositions according to the present invention are administered by injection, e.g. via a pen or a syringe, it is typically administered 3 times per day, preferably before meals. It is preferred that each administration comprises less than about 500  $\mu$ L, or less than about 200  $\mu$ L since larger injection volumes are unpleasant for the patient. When the pharmaceutical compositions according to the present invention are administered by a pump, it is typically administered continuously or discontinuously via at least 10 administrations or more per day. In one embodiment of the invention the method of treatment comprises administration of an effective amount of the pharmaceutical composition which is from about 30  $\mu$ L/day to about 600  $\mu$ L/day, such as from about 60  $\mu$ L/day to about 360  $\mu$ L/day. In another embodiment of the invention the method comprises a pharmaceutical composition for administration by subcutaneous injection. In another embodiment of the invention the method comprises a pharmaceutical composition for administration by a pump. In another embodiment of the invention the method comprises administration by a pump which delivers a discontinuous amount of said pharmaceutical composition. In another embodiment of the invention the method comprises administration by a pump which delivers a discontinuous amount of said pharmaceutical composition wherein said discontinuous administration of said pharmaceutical composition is by a pulse dosing for a period of time which is less than the period between pulses.

In another aspect the present invention relates to the use of an insulinotropic peptide and a meal-related insulin peptide for the manufacture of a pharmaceutical composition for par-

enteral administration, which composition comprises an insulintropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative, and optionally an isotonicity agent. In one embodiment of the invention the use comprises a pharmaceutical composition for administration by subcutaneous injection. In another embodiment of the invention the use  
5 comprises a pharmaceutical composition for administration by a pump. In another embodiment of the invention the use comprises administration by a pump which delivers a discontinuous amount of said pharmaceutical composition. In another embodiment of the invention the use comprises administration by a pump which delivers a discontinuous amount of said pharmaceutical composition wherein said discontinuous administration of said pharmaceuti-  
10 cal composition is by a pulse dosing for a period of time which is less than the period between pulses.

In another aspect the present invention relates to the use of an insulin peptide and an insulintropic peptide for the manufacture of a pharmaceutical composition for the treatment of  
15 hyperglycemia by parenteral administration, which composition comprises an insulin peptide, an insulintropic peptide, a pharmaceutically acceptable buffer, a pharmaceutically acceptable preservative, a surfactant and optionally an isotonicity agent.

## EXAMPLES

### Example 1. In vivo pig data of mixtures.

- 5 Two mixtures of insulin aspart (Asp<sup>B28</sup>-human insulin) and Liraglutide (Arg<sup>34</sup>Lys<sup>26</sup>N<sup>ε</sup>(γ-Glu(N<sup>α</sup>-hexadecanoyl))GLP-1(7-37)), with insulin aspart labelled in Tyr A14 with <sup>125</sup>I, were prepared for subcutaneous administration to pigs. The study design was simultaneous measuring of insulin aspart disappearance from the injection site by external gamma counting, and monitoring of Liraglutide plasma concentration time course for up to 72 hours.

10

#### Aspart formulation (reference)

600 μM Aspart (with tracer), 300 μM Zn(Ac)<sub>2</sub>, pH 7.4, 30 mM phenol, 1.6 % glycerol.

#### Mix Aspart:Liraglutide formulation, 1:1

600 μM Aspart (with tracer), 600 μM Liraglutide, 300 μM Zn(Ac)<sub>2</sub>, pH 7.4, 30 mM phenol, 1.6 % glycerol.

15

#### Mix Aspart:Liraglutide formulation, 1:5

600 μM Aspart (with tracer), 3000 μM Liraglutide, 300 μM Zn(Ac)<sub>2</sub>, pH 7.4, 30 mM phenol, 1.6 % glycerol.

- 20 Six normal and healthy pigs (Dansk Landrace, LDY) having a body weight of 80 kg to 100 kg were included in the study. The pigs were each administered 100 μL insulin aspart formulation (reference) at one side of the neck and 100 μL mix aspart/liraglutide formulation at the opposite side. Disappearance courses of radiolabelled insulin aspart were measured at both injection sites in 6 pigs for the insulin aspart reference, and in 3 pigs for each mix 1:1 and 1:5. Simultaneously blood samples were collected over a period of 72 hours to monitor the plasma concentration time course of Liraglutide.

25

#### Average disappearance curves with standard deviations

- 30 The average disappearance curves are shown in figure 1. The disappearance versus time of insulin aspart from the subcutaneous tissue following administration of the 1:5 mixture was only slightly slower than for both the reference and the 1:1 mixture. The mean (SD) time point for 75%, 50% and 25% of the remaining radioactivity following injection, were calculated, please refer to table 1 below.

**Table 1.** Summary of disappearance study.

	Insulin Aspart reference (n=6)	Mix 1:1 (n=3)	Mix 1:5 (n=3)
T75% (h)	0.75 ± 0.05	0.79 ± 0.07	0.83 ± 0.03
T50% (h)	1.60 ± 0.11	1.70 ± 0.13	1.78 ± 0.05
T25% (h)	2.79 ± 0.26	2.96 ± 0.23	3.14 ± 0.18

### Pharmacokinetics of Liraglutide

5

Pharmacokinetics were calculated on plasma concentration time data. Based on AUC it was concluded that absorption of liraglutide was independent of the mixture applied, since liraglutide from the 1:5 formulation give rise to a 5-fold increase in AUC, thereby confirming unchanged relative bioavailability of Liraglutide.

10

Based on above PK parameters, a simulation was performed illustrating co-administration (with Aspart) of 0.2 nmol/kg Liraglutide at mealtimes (breakfast, lunch, and dinner). App. 0.2 nmol/kg of Liraglutide at meal time are providing a satisfying Liraglutide plasma level indicating that 1:1 is the most likely Aspart:Liraglutide ratio.

15

Figures 2 and 3 show the plasma levels of liraglutide after subcutaneous injections of the mixtures described above.

**Table 2.** Liraglutide PK parameters n=3

	<b>t<sub>max</sub></b> (hr)	<b>C<sub>max</sub></b> (pmol/L)	<b>t<sub>1/2</sub></b> (hr)	<b>AUC</b> (hr*pmol/L)	<b>Extr</b> (%)
<b>2) 1:1</b>					
Mean	12.0	2180	26.2	123488	18
SD	10.4	209	5.7	34562	6
Harmonic Mean	8.0	2166	25.5	117918	17
<b>3) 1:5</b>					
Mean	8.0	21187	19.2	665435	9
SD	4.0	8751	2.8	59264	3
Harmonic Mean	6.5	19230	18.9	661980	8


**Example 2.**

Two pharmaceutical compositions were prepared according to the description of the present invention. Both pharmaceutical compositions comprised the meal related insulin Asp<sup>B28</sup>-  
 5 human insulin (aspart) and the insulinotropic peptide Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) (liraglutide). In both pharmaceutical compositions aspart concentration is 0.6 mM and liraglutide concentration is 1.2 mM. Furthermore both compositions contained 10 mM NaCl, 8 mM phosphate buffer, 14 mg/ml propylene glycol, 40 mM phenol. Turbidimetric measurements of compositions without poloxamer 188 (x) and with poloxamer  
 10 188 (◇) (500 ppm) are shown for 8 and 7 days, respectively (Figure 4).

**Example 3.**

Two pharmaceutical compositions were prepared according to the description of the present  
 15 invention. Both pharmaceutical compositions comprised the meal related insulin Asp<sup>B28</sup>-human insulin (aspart) and the insulinotropic peptide Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) (liraglutide). In both pharmaceutical compositions aspart concentration is 0.6 mM and liraglutide concentration is 1.2 mM. Furthermore both compositions contained 0.35 mM 5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yloxy]pentanoic acid,  
 20 10 mM bicine buffer, 14 mg/ml propylene glycol, 40 mM phenol. Turbidimetric measurements of pharmaceutical compositions without poloxamer 188 (x) and with poloxamer 188 (◇) (50 ppm) were performed for 13 days (figure 5).

5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yloxy]pentanoic acid



25

**Example 4**

30 The following pharmaceutical compositions are prepared :

F1. 1.2 mM liraglutide, 14 mg/ml propylene glycol, 40 mM phenol, 3 Zn/hex, aspart 0.6 mM, 8 mM bicine, 50 ppm poloxamer 188, pH 7.7.

F2. 1.2 mM liraglutide, 14 mg/ml propylene glycol, 40 mM phenol, 3 Zn/hex, aspart 0.6 mM, 8 mM bicine, pH 7.7.

5

Physical stability of the pharmaceutical compositions is evaluated by means of an accelerated stressed test. The stressed test is performed as a rotation test. 50µL air is added to 5 cartridges (glass vials) of each formulation. The cartridges are rotated with a frequency of 30 rotations per minute for 4 hours daily. The test is stopped after 22 days of rotation. The inspection of the cartridges is followed daily or as required. The turbidity of the formulation is characterized by nephelometric measurement of the turbidity on a HACH Turbidimeter 2100AN. The turbidity measurement of a liquid is specified in "Nephelometric Turbidity Unit" (NTU). Physical instability of the protein is characterised by high turbidity measurements.

The experiments show that the NTU measurements increase much more rapidly in the F2 composition as compared to the NTU trace of the F1 composition.

15

### Example 5

20

#### Thioflavin T (ThT) fibrillation assay: Principle and examples

Low physical stability of a peptide may lead to amyloid fibril formation, which is observed as well-ordered, thread-like macromolecular structures in the sample eventually resulting in gel formation. This has traditionally been measured by visual inspection of the sample. However, that kind of measurement is very subjective and depending on the observer. Therefore, the application of a small molecule indicator probe is much more advantageous. Thioflavin T (ThT) is such a probe and has a distinct fluorescence signature when binding to fibrils [Naiki et al. (1989) Anal. Biochem. **177**, 244-249; LeVine (1999) Methods. Enzymol. **309**, 274-284].

25

30

The time course for fibril formation can be described by a sigmoidal curve with the following expression [Nielsen et al. (2001) Biochemistry **40**, 6036-6046]:

$$F = f_i + m_i t + \frac{f_f + m_f t}{1 + e^{-[(t-t_0)/\tau]}} \quad \text{Eq.(1)}$$

Here,  $F$  is the ThT fluorescence at the time  $t$ . The constant  $t_0$  is the time needed to reach 50% of maximum fluorescence. The two important parameters describing fibril formation are the lag-time calculated by  $t_0 - 2\tau$  and the apparent rate constant  $k_{app} = 1/\tau$ :

5            Formation of a partially folded intermediate of the peptide is suggested as a general initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assembly and the fibrillation proceeds. The lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.

10

### Sample preparation

          Samples were prepared freshly before each assay. Each sample composition is described in the legends. The pH of the sample was adjusted to the desired value using appropriate amounts of concentrated NaOH and HClO<sub>4</sub>. Thioflavin T was added to the samples  
15 from a stock solution in H<sub>2</sub>O to a final concentration of 1  $\mu$ M.

          Sample aliquots of 200  $\mu$ l were placed in a 96 well microtiter plate (Packard Opti-Plate™-96, white polystyrene). Usually, eight replica of each sample (corresponding to one test condition) were placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen).

20

### Incubation and fluorescence measurement

          Incubation at given temperature, shaking and measurement of the ThT fluorescence emission were done in a Fluoroskan Ascent FL fluorescence platereader (Thermo Labsystems). The temperature was adjusted to 37 °C. The orbital shaking was adjusted to 960 rpm  
25 with an amplitude of 1 mm in all the presented data. Fluorescence measurement was done using excitation through a 444 nm filter and measurement of emission through a 485 nm filter.

          Each run was initiated by incubating the plate at the assay temperature for 10 min. The plate was measured every 20 minutes for typically 45 hours. Between each measurement,  
30 the plate was shaken and heated as described.

### Data handling

          The measurement points were saved in Microsoft Excel format for further processing and curve drawing and fitting was performed using GraphPad Prism. The background  
35 emission from ThT in the absence of fibrils was negligible. The data points are typically a

mean of eight samples and shown with standard deviation error bars. Only data obtained in the same experiment (i.e. samples on the same plate) are presented in the same graph ensuring a relative measure of fibrillation between experiments.

The data set may be fitted to Eq. (1). However, since full sigmoidal curves in this case are not always achieved during the measurement time, the degree of fibrillation is expressed as ThT fluorescence tabulated as the mean of the eight samples and shown with the standard deviation at various time points.

#### Example 6

A formulation of insulin aspart and liraglutide in a 1:2 mix ratio in water adjusted to pH 7.7 is highly physical unstable as seen in Figure 6. The ThT fluorescence signal increases instantaneously and reaches a plateau before 10 hours of assay time. However, the addition of Poloxamer 188 stabilises this formulation. Both at 50 ppm and 200 ppm Poloxamer 188, the insulin aspart – liraglutide mix formulation does not exhibit any increase in ThT fluorescence above background level, hence these samples are fully physical stable and do not fibrillate.

#### Example 7

Also Polysorbate 20 is capable of stabilising an insulin aspart – liraglutide 1:2 mix formulated in water, see Figure 7. The presence of 200 ppm Polysorbate 20 fully suppresses fibrillation.

#### Example 8

When formulating insulin aspart and liraglutide in a 1:2 mix ratio in sodium phosphate buffer, the sample is highly physically unstable, see Figure 8. The presence of 50 ppm or 200 ppm Poloxamer 188 prolongs the lag time before on-set of fibrillation: from the instantaneous fibrillation in the absence of Poloxamer 188, it is longer than 15 hours in the presence of either 50 ppm or 200 ppm Poloxamer 188. The sample with the highest Poloxamer 188 concentration exhibits the lowest ThT signal after 40 hours of assay time.

#### Example 9

Polysorbate 20 does also stabilise insulin aspart – liraglutide 1:2 mixes formulated in sodium phosphate buffer, see Figure 9. The presence of 100 ppm Polysorbate 20 increases the lag time to longer than 5 hours compared to the sample without Polysorbate 20. The presence of 200 ppm Polysorbate 20 fully suppresses fibrillation of the sample.

**Example 10**

Formulations where insulin aspart and liraglutide are mixed in a 1:5 ratio are also highly physical unstable. These formulations are stabilised by the presence of 100 ppm Poloxamer 188 or 200 ppm Polysorbate 20. This is observed as a prolongation of the lag time before on-set of fibrillation in the presence of either Poloxamer 188 or Polysorbate 20 compared with a similar formulation without either Poloxamer 188 or Polysorbate 20.

10

15

20

**CLAIMS**

- 5 1. A soluble pharmaceutical composition for parenteral administration, which comprises an insulinotropic peptide, a meal-related insulin peptide, a pharmaceutically acceptable preservative and optionally an isotonicity agent.
- 10 2. The pharmaceutical composition according to claim 1, wherein the pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from about pH 7.0 to about pH 9.0.
- 15 3. The pharmaceutical composition according to claim 1, wherein the pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from about pH 7.0 to about pH 8.0.
4. The pharmaceutical composition according to any one of the claims 1-3, wherein the composition is a solution.
- 20 5. The pharmaceutical composition according to any one of the claims 1-3, wherein the composition is a solid.
6. The pharmaceutical composition according to claim 5, which is to be reconstituted with an aqueous solution such as a buffer or water for injection.
- 25 7. The pharmaceutical composition according to any one of the preceding claims, which is suitable for administration by injection or infusion.
8. The pharmaceutical composition according to any one of the preceding claims, wherein said meal-related insulin peptide has a time action of less than 4 hours.
- 30 9. The pharmaceutical composition according to any one of the preceding claims, wherein said meal-related insulin peptide is human insulin, an analogue of human insulin, a derivative of human insulin or a derivative of a human insulin analogue.

10. The pharmaceutical composition according to claim 9, wherein said meal-related insulin peptide is human insulin.

5 11. The pharmaceutical composition according to claim 9, wherein said meal-related insulin peptide is a human insulin analogue.

12. The pharmaceutical composition according to claim 11, wherein said meal-related human insulin analogue is Asp<sup>B28</sup>-human insulin.

10 13. The pharmaceutical composition according to claim 11, wherein said meal-related human insulin analogue is Lys<sup>B28</sup>,Pro<sup>B29</sup>-human insulin.

14. The pharmaceutical composition according to claim 11, wherein said meal-related human insulin analogue is Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin.

15

15. The pharmaceutical composition according to claim 11, wherein said meal-related human insulin analogue is des(B30) human insulin.

20

16. The pharmaceutical composition according to claim 9, wherein said meal-related insulin peptide is a derivative of a human insulin analogue.

25

17. The pharmaceutical composition according to any of the preceding claims, wherein the concentration of said meal-related insulin peptide is in the range from about 1.6 mg/mL to about 5.6 mg/mL, or from about 2.6 mg/mL to about 4.6 mg/mL, or from about 3.2 mg/mL to about 4.0 mg/mL.

30

18. The pharmaceutical composition according to any of claims 1-16, wherein the concentration of said meal-related insulin peptide is in the range from about 1 mg/mL to about 10 mg/mL, or from about 2.5 mg/mL to about 8.75 mg/mL, or from about 3.5 mg/mL to about 8.75 mg/mL, or from about 5 mg/mL to about 8.75 mg/mL.

19. The pharmaceutical composition according to any of the preceding claims, comprising two different insulin peptides.

20. The pharmaceutical composition according to any of the preceding claims, wherein said insulinotropic peptide is GLP-1(7-37) (SEQ ID NO. 1), a GLP-1(7-37) analogue, a derivative of GLP-1(7-37), or a derivative of a GLP-1(7-37) analogue.

5 21. The pharmaceutical composition according to claim 20, wherein said GLP-1(7-37) analogue is selected from the group consisting of Arg<sup>34</sup>-GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-36)-amide, Gly<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Lys<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Lys<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Arg<sup>22</sup>-GLP-1(7-36)-amide,  
10 Val<sup>8</sup>Arg<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>His<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>His<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>19</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Val<sup>25</sup>-GLP-1(7-37), Val<sup>8</sup>Tyr<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Leu<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Tyr<sup>18</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>His<sup>37</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Val<sup>25</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Val<sup>25</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Val<sup>25</sup>-GLP-1(7-37), analogues  
15 thereof and derivatives of any of these.

22. The pharmaceutical composition according to claim 20, wherein said derivative of a GLP-1(7-37) analogue is GLP-1(7-36)-amide.

20 23. The pharmaceutical composition according to any one of claims 1-20, wherein said insulinotropic peptide is a derivative of GLP-1(7-37) or a derivative of a GLP-1(7-37) analogue having a lysine residue, such as one lysine, wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.

25 24. The pharmaceutical composition according to claim 23, wherein said lipophilic substituent has from 8 to 40 carbon atoms, preferably from 8 to 24, eg 12-18.

25. The pharmaceutical composition according to any one of claims 23-24, wherein said spacer is present and is selected from an amino acid, eg. beta-Ala, L-Glu, aminobutyryl.

30

26. The pharmaceutical composition according to any one of claims 1-20, wherein said insulinotropic peptide is a dipeptidyl aminopeptidase IV protected GLP-1 compound.

35 27. The pharmaceutical composition according to any one of claims 1-20 and 26, wherein said insulinotropic peptide is a plasma stable GLP-1 compound.

28. The pharmaceutical composition according to any one of claims 1-20, 24-25 and 27, wherein said derivative of a GLP-1(7-37) analogue is Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37).

5

29. The pharmaceutical composition according to any one of claims 20-28, wherein said insulinotropic peptide has from 27 to 43 amino acid residues, preferable from 28 to 38 amino acid residues, even more preferable from 30 to 34 amino acid residues.

10

30. The pharmaceutical composition according to any one of claims 20-29, wherein the concentration of said insulinotropic peptide is from about 1 mg/mL to about 25 mg/mL, from about 2 mg/mL to about 15 mg/mL, from about 5 mg/mL to about 12mg/mL, or from about 8 mg/mL to about 11 mg/mL.

15

31. The pharmaceutical composition according to any one of claims 1-19, wherein said insulinotropic peptide is exendin-4 (SEQ ID NO 2), an exendin-4 analogue, a derivative of exendin-4, or a derivative of an exendin-4 analogue.

20

32. The pharmaceutical composition according to claim 31, wherein said insulinotropic peptide is exendin-4 (SEQ ID NO. 2).

25

33. The pharmaceutical composition according to claim 31, wherein said exendin-4 analogue is exendin-3 or ZP-10 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH<sub>2</sub>, SEQ ID. NO. 3).

30

34. The pharmaceutical composition according to claim 31, wherein said derivative of an exendin-4 analogue is an acylated exendin-4 analogue or a pegylated exendin-4 analogue.

35. The pharmaceutical composition according to claim 31, wherein said insulinotropic peptide is a derivative of exendin-4 or a derivative of an exendin-4 analogue having a lysine residue, such as one lysine, wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.

35

36. The pharmaceutical composition according to claim 35, wherein said lipophilic substituent has from 8 to 40 carbon atoms, preferably from 8 to 24, eg 12-18.

37. The pharmaceutical composition according to any one of claims 35-36, wherein said spacer is present and is selected from an amino acid, eg. beta-Ala, L-Glu, aminobutyroyl.

5 38. The pharmaceutical composition according to any one of claims 1-19, 31 and 35-38, wherein said insulintropic peptide is a dipeptidyl aminopeptidase IV protected exendin-4 compound.

10 39. The pharmaceutical composition according to any one of claims 1-19, 31 and 34-38, wherein said insulintropic peptide is a plasma stable exendin-4 compound.

15 40. The pharmaceutical composition according to any of claims 31-39, wherein said insulintropic peptide has from 30 to 48 amino acid residues, from 33 to 45 amino acid residues, preferable from 35 to 43 amino acid residues, even more preferable from 37 to 41 amino acid residues.

20 41. The pharmaceutical composition according to any one of claims 20-29 and 31-40, wherein the concentration of said insulintropic peptide is from about 5  $\mu\text{g}/\text{mL}$  to about 10  $\text{mg}/\text{mL}$ , from about 5  $\mu\text{g}/\text{mL}$  to about 5  $\text{mg}/\text{mL}$ , from about 0.1  $\text{mg}/\text{mL}$  to about 3  $\text{mg}/\text{mL}$ , or from about 0.2  $\text{mg}/\text{mL}$  to about 1  $\text{mg}/\text{mL}$ .

25 42. The pharmaceutical composition according to any of the preceding claims, wherein the isoelectric point of said insulintropic peptide is from 3.0 to 7.0, from 4.0 to 6.0, preferable from 4.2 to 5.5, even more preferable from 4.3 to 5.2.

43. The pharmaceutical composition according to any one of the preceding claims, comprising zinc.

30 44. The pharmaceutical composition according to claim 43, wherein the molar ratio of zinc to insulin peptide is from 1/6 to 1/2 mole/mole, preferable from 3/12 to 5/12 mole/mole.

35 45. The pharmaceutical composition according to any one of claims 1-10, wherein said meal-related insulin peptide is human insulin and said insulintropic peptide is  $\text{Arg}^{34}$ ,  $\text{Lys}^{26}(\text{N}^{\epsilon}\text{-}(\gamma\text{-Glu}(\text{N}^{\alpha}\text{-hexadecanoyl})))\text{-GLP-1(7-37)}$ .

46. The pharmaceutical composition according to claim 45, wherein the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from from about 5 mg/mL to about 15 mg/mL and the concentration of human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL.

5

47. The pharmaceutical composition according to any one of claims 1-8, wherein said insulin peptide is Asp<sup>B28</sup>-human insulin and said insulinotropic peptide is Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37).

10 48. The pharmaceutical composition according to claim 47, wherein the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 5 mg/mL to about 15 mg/mL and the concentration of Asp<sup>B28</sup>-human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL.

15 49. The pharmaceutical composition according to claim 47, wherein the concentration of Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(γ-Glu(N<sup>α</sup>-hexadecanoyl)))-GLP-1(7-37) is in the range from about 5 mg/mL to about 15 mg/mL and the concentration of Asp<sup>B28</sup>-human insulin is in the range from about 3.4 mg/mL to about 3.8 mg/mL.

20 50. The pharmaceutical composition according to any one of claims 1-8, wherein said insulin peptide is Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin and said insulinotropic peptide is ZP-10 (HGEFT-FTSDLSKQMEEEAVRLFIEWLKNNGPSSGAPPSKKKKKK-NH<sub>2</sub>, SEQ ID. NO. 3).

25 51. The pharmaceutical composition according to claim 50, wherein the concentration of Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin is in the range from about 3.2 mg/mL to about 4.0 mg/mL.

52. The pharmaceutical composition according to any one of claims 50-51, wherein the concentration of ZP-10 is in the range from about 0.1 mg/mL to about 3 mg/mL.

30 53. The pharmaceutical composition according to any one of the preceding claims, wherein said preservative is phenol, m-cresol or a mixture thereof.

54. The pharmaceutical composition according to any one of the preceding claims, wherein said pharmaceutical composition comprises a buffer.

35

55. The pharmaceutical composition according to claim 54, wherein said buffer is phosphate, TRIS, HEPES, glycine, N-glycylglycine, citrate or a mixture thereof.

56. The pharmaceutical composition according to any one of the preceding claims, wherein  
5 said pharmaceutical composition comprises an isotonicity agent.

57. The pharmaceutical composition according to claim 56, wherein said isotonicity agent is not a salt.

10 58. The pharmaceutical composition according to claim 57, wherein said isotonicity agent is selected from mannitol, sorbitol, glycerol, propylene glycol or a mixture thereof.

59. The pharmaceutical composition according to any one of the preceding claims, which further comprises a stabiliser.

15

60. The pharmaceutical composition according to claim 59, wherein said stabiliser is selected from the group consisting of L-histidine, imidazole and L-arginine.

20 61. The pharmaceutical composition according to claim 59, wherein said stabiliser is a polyethylene glycol.

62. The pharmaceutical composition according to any one of the preceding claims, which further comprises a surfactant.

25 63. The pharmaceutical composition according to claim 62, wherein said surfactant is a poloxamer.

64. The pharmaceutical composition according to claim 63, wherein said surfactant is a poloxamer 188.

30

65. The pharmaceutical composition according to claim 63, wherein said surfactant is selected from the group consisting of poloxamer 407, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 237, poloxamer 331 and poloxamer 338.

66. The pharmaceutical composition according to claim 62, wherein said surfactant is a polysorbate 20 (Tween-20).

5 67. The pharmaceutical composition according to any one of claims 62-66, wherein the concentration of said surfactant is from about 5 mg/L to about 3000 mg/L.

68. The pharmaceutical composition according to any one of claims 62-66, wherein the concentration of said surfactant is from about 10 mg/L to about 500 mg/L.

10 69. The pharmaceutical composition according to any one of claims 62-66, wherein the concentration of said surfactant is from about 20 mg/L to about 300 mg/L.

70. The pharmaceutical composition according to any one of claims 62-66, wherein the concentration of said surfactant is from about 50 mg/L to about 200 mg/L.

15

71. The pharmaceutical composition according to any one of claims 62-70, comprising two different surfactants.

20 72. The pharmaceutical composition according to claim 71, comprising poloxamer 188 and polysorbate 20 (Tween-20).

73. A method for treatment of hyperglycemia comprising parenteral administration of an effective amount of the pharmaceutical composition according to any one of claims 1-72.

25 74. The method according to claim 73, wherein said effective amount of the pharmaceutical composition is from about 30  $\mu$ L/day to about 600  $\mu$ L/day, such as from about 60  $\mu$ L/day to about 360  $\mu$ L/day.

30 75. The method according to any one of claims 73-74, wherein administration is by subcutaneous injection.

76. The method according to anyone of claims 73-75, wherein administration is by a pump.

35 77. The method according to anyone of claims 73-76, wherein administration is by a pump which delivers a discontinuous amount of said pharmaceutical composition.

78. The method according to claim 77, wherein said discontinuous administration of said pharmaceutical composition is by a pulse dosing for a period of time which is less than the period of time between pulses.

5

79. Use of an insulin peptide and an insulintropic peptide for the manufacture of a pharmaceutical composition according to any one of claims 1-72.

80. The use according to claim 79, wherein said pharmaceutical composition is for subcutaneous injection.

10

81. The use according to anyone of claims 79-80, wherein administration is by a pump.

82. The use according to anyone of claims 79-81, wherein administration is by a pump which delivers a discontinuous amount of said pharmaceutical composition.

15

83. The use according to claim 82, wherein said discontinuous administration of said pharmaceutical composition is by a pulse dosing for a period of time which is less than the period of time between pulses.

20


84. Use of an insulin peptide and an insulintropic peptide for the manufacture of a pharmaceutical composition according to any one of claims 1-72 for the treatment of hyperglycemia.

85. Use of an insulin peptide and an insulintropic peptide for the manufacture of a pharmaceutical composition according to any one of claims 1-72 for the treatment of binge eating or bulimia.

25

Figure 1.

5



10

Figure 2.

5




Figure 3.

5




Figure 4

5




Figure 5

5





Figure 6


5



	10 h	SD	40 h	SD
■ Reference	3227	90	3203	69
△ + 50 ppm Poloxamer-188	33	0	33	1
* + 200 ppm Poloxamer-188	34	0	35	2

Figure 7


5



	10 h	SD	40 h	SD
● Reference	2734	73	2726	48
■ + 200 ppm Polysorbate-20	29	1	35	5

Figure 8


5



	10 h	SD	30 h	SD	40 h	SD
◆ Reference	2909	74	2900	71	2880	92
▲ +50 ppm Poloxamer-188	30	0	2118	1365	3038	66
▼ +200 ppm Poloxamer-188	30	0	439	1155	1185	1594

Figure 9

5



	5 h	SD	40 h	SD
■ Reference	2851	101	2880	92
▲ +100 ppm Pololysorbate-20	28	0	2558	1026
▼ +200 ppm Pololysorbate-20	28	0	33	3

## SEQUENCE LISTING

5 <110> Novo Nordisk A/S

<120> Pharmaceutical composition containing insulin and insulinotropic peptide

10 <130> 6618

<160> 3

15 <170> PatentIn version 3.1

<210> 1

<211> 31

<212> PRT

20 <213> Homo sapiens

<400> 1

25 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly  
20 25 30

30

<210> 2

<211> 39

<212> PRT

35 <213> Glia monster

<220>

<221> MOD\_RES

<222> (39)..(39)

40 <223> Serine at position 39 is amidated

<400> 2

45 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

50

Ser Gly Ala Pro Pro Pro Ser  
35

5

<210> 3

<211> 44

<212> PRT

10 <213> Artificial sequence

<220>

<223> Synthetic construct

15

<220>

<221> MOD\_RES

<222> (44)..(44)

<223> Lysine at position 44 is amidated

20

<400> 3

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

25

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

30

Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys  
35 40

35

40

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK2004/000788

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K38/26 A61K38/28 A61P3/04 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, Sequence Search, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 01/00223 A (MINIMED INC.) 4 January 2001 (2001-01-04) the whole document see especially: page 2, line 18 - line 32 page 3, line 4 - line 20 page 4, line 15 - line 32 page 5, line 4 - page 6, line 31 page 7, line 22 - page 8, line 11 page 9; example 2 page 12 - page 20; claims 1-7, 9-14, 21-23, 25-34, 40, 51-54, 58-63, 65-68 ----- -/--	1-85

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

21 March 2005

Date of mailing of the international search report

08/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

## INTERNATIONAL SEARCH REPORT

 Inter Application No  
 PCT/DK2004/000788

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 458 924 B2 (KNUDSEN, L.B. ET AL.) 1 October 2002 (2002-10-01) the whole document see especially: column 153, line 46 - column 157, line 25 column 173; example 37 column 176, line 58 - column 178, line 38; table 1 column 200 - column 206; examples 101-105 column 249 - column 250; claims 1-16,19,20 -----	1-85
A	WO 03/020201 A (ELI LILLY AND COMPANY) 13 March 2003 (2003-03-13) the whole document see especially: page 6, line 24 - page 13, line 13 page 41 - page 42; examples 6,7 page 50 - page 53; examples 11-17 -----	1-85
A	US 5 514 646 A (CHANCE, R.E. ET AL.) 7 May 1996 (1996-05-07) the whole document see especially: column 1, line 13 - column 2, line 5 column 3, line 13 - column 4, line 65 column 49, line 33 - column 53, line 62 column 54 - column 60; claims 1-81 -----	1-85
A	RASKIN, P. ET AL.: "Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes" DIABETES CARE, vol. 26, no. 9, September 2003 (2003-09), pages 2598-2603, XP002321785 the whole document -----	1-85
A	MEIER, J.J. ET AL.: "Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes" JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 88, no. 6, June 2003 (2003-06), pages 2719-2725, XP002321786 the whole document -----	1-85

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK2004/000788

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 73-78 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int	Patent Application No
PCT/DK2004/000788	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 0100223	A	04-01-2001	AU 5760900 A	31-01-2001
			CA 2369839 A1	04-01-2001
			EP 1196189 A2	17-04-2002
			JP 2003503356 T	28-01-2003
			WO 0100223 A2	04-01-2001
US 6458924	B2	02-08-2001	US 6384016 B1	07-05-2002
			US 6268343 B1	31-07-2001
			US 2001011071 A1	02-08-2001
			US 2003199672 A1	23-10-2003
			AU 732957 B2	03-05-2001
			AU 3847897 A	19-03-1998
			AU 4112497 A	19-03-1998
			BR 9711437 A	18-01-2000
			CA 2264243 A1	05-03-1998
			CA 2468374 A1	05-03-1998
			CN 1232470 A	20-10-1999
			CZ 9900629 A3	14-07-1999
			WO 9808871 A1	05-03-1998
			WO 9808872 A1	05-03-1998
			EP 0944648 A1	29-09-1999
			EP 0929576 A1	21-07-1999
			HU 9903714 A2	28-03-2000
			JP 2000500505 T	18-01-2000
			JP 3149958 B2	26-03-2001
			JP 2000517308 T	26-12-2000
			JP 2001011095 A	16-01-2001
			KR 2000035964 A	26-06-2000
			MA 24129 A1	01-10-1997
			NO 990950 A	28-04-1999
			PL 331896 A1	16-08-1999
			RU 2214419 C2	20-10-2003
			US 2004127418 A1	01-07-2004
			US 2002025933 A1	28-02-2002
			ZA 9707791 A	02-03-1998
			ZA 9707828 A	02-03-1998
			AU 2610899 A	15-09-1999
			WO 9943707 A1	02-09-1999
			EP 1062240 A1	27-12-2000
			JP 2002506792 T	05-03-2002
			AU 2610599 A	15-09-1999
			WO 9943705 A1	02-09-1999
			EP 1056774 A1	06-12-2000
			JP 2002508162 T	19-03-2002
			AT 265224 T	15-05-2004
			AU 2610699 A	15-09-1999
			AU 2610799 A	15-09-1999
			DE 69916811 D1	03-06-2004
WO 9943706 A1	02-09-1999			
WO 9943341 A1	02-09-1999			
EP 1060191 A1	20-12-2000			
EP 1061946 A1	27-12-2000			
JP 2002504518 T	12-02-2002			
JP 2002512175 T	23-04-2002			
ZA 9901569 A	27-08-1999			
ZA 9901570 A	02-09-1999			
WO 03020201	A	13-03-2003	CA 2452044 A1	13-03-2003

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No PCT/DK2004/000788
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03020201	A	EP 1432430 A2	30-06-2004
		MX PA04001560 A	17-05-2004
		WO 03020201 A2	13-03-2003
		US 2004235710 A1	25-11-2004
US 5514646	A	07-05-1996	
		US 5700662 A	23-12-1997
		AT 133961 T	15-02-1996
		AU 630912 B2	12-11-1992
		AU 4922690 A	16-08-1990
		BG 60769 B2	29-02-1996
		CA 2009579 A1	09-08-1990
		CN 1044820 A ,C	22-08-1990
		CN 1148984 A ,C	07-05-1997
		CY 1911 A	06-02-1990
		DE 69025210 D1	21-03-1996
		DE 69033889 D1	07-02-2002
		DE 69033889 T2	22-08-2002
		DK 383472 T3	06-05-1996
		DK 678522 T3	11-03-2002
		EP 0383472 A2	22-08-1990
		EP 0678522 A1	25-10-1995
		ES 2083424 T3	16-04-1996
		ES 2170122 T3	01-08-2002
		FI 95915 B	29-12-1995
		GR 3019501 T3	31-07-1996
		HK 60296 A	12-04-1996
		HU 57795 A2	30-12-1991
		HU 9500171 A3	28-08-1995
		IE 73251 B1	21-05-1997
		IL 93282 A	31-08-1995
		JP 2110045 C	21-11-1996
		JP 2264798 A	29-10-1990
		JP 8022878 B	06-03-1996
		LU 88830 A9	06-01-1997
		LU 88831 A9	10-01-1997
		LV 10291 A ,B	20-10-1994
		NL 960026 I1	06-01-1997
NO 900615 A ,B,	10-08-1990		
NO 950721 A	10-08-1990		
NZ 232375 A	28-04-1992		
PT 93057 A ,B	31-08-1990		
RU 2109749 C1	27-04-1998		
KR 169727 B1	15-01-1999		
MX 19389 A	28-02-1994		
ZA 9000838 A	30-10-1991		